Bolt, US0977022039

Bolt Biotherapeutics stock fell 1.71 percent on October 2

Published on 10/04/2026 at 17:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Bolt Biotherapeutics stock fell to USD 3.45 on October 2, 2026, while its Q2 EPS loss reached USD 4.57. The consensus target stands at USD 14.50.

Bolt, US0977022039, Illustration mit AI erstellt.

Bolt Biotherapeutics (ISIN US0977022039) fell 1.71 percent to USD 3.45 on Nasdaq on October 2, 2026, leaving the clinical-stage biotechnology company near the bottom of its USD 3.10 to USD 7.20 52-week range. The latest company results add a second pressure point: Q2 2026 GAAP earnings per share came in at negative USD 4.57, while the published estimate was negative USD 21.06.

Second-quarter loss sets the tone

Yahoo Finance lists Q2 FY26 GAAP EPS at negative USD 4.57 and the estimate at negative USD 21.06, alongside earnings of negative USD 7.72 million. The comparison is favorable against the published estimate on the per-share line, but the absolute loss keeps financing and clinical execution central to the equity story.

StockTitan lists August 11, 2026, as the date of Bolt's second-quarter results release. The company is developing immune-stimulating antibody conjugates, so clinical milestones matter more to valuation than near-term commercial revenue.

Analyst target versus market value

The valuation gap is unusually wide in percentage terms. MarketBeat reports a consensus price target of USD 14.50, a Hold consensus, one Sell rating, one Hold rating and two Buy ratings. At USD 3.45, the price lies 76.2 percent below that target, calculated from the same currency.

The contrast with the chart is clear: the October 2 price was USD 0.35 above the 52-week low, but USD 3.75 below the 52-week high. Market capitalization stood at USD 6.7 million on October 2, 2026, making clinical data and cash management material drivers for the stock.

Bolt stock stays near yearly low

Bolt Biotherapeutics stock was last at USD 3.45 on Nasdaq on October 2, 2026. The 1.71 percent daily decline and the position near the 52-week low leave the market focused on whether upcoming clinical progress can offset the company's continuing quarterly losses.